Stratos Wealth Partners’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
Stratos Wealth Partners's GANX Position: Q3 2026 in Review
Stratos Wealth Partners sold out of Gain Therapeutics (GANX) in Q3 2026, closing a stake of 200,000 shares — an estimated $406K sold.
Stratos Wealth Partners first reported a position in GANX in Q1 2026 and held it in 2 quarters. The position peaked at $406K in Q2 2026. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.
- Stratos Wealth Partners reported no remaining Gain Therapeutics position as of Q3 2026 after selling out during the quarter.
- Stratos Wealth Partners sold 200,000 Gain Therapeutics shares in Q3 2026, an estimated $406K.
- Stratos Wealth Partners first reported a position in Gain Therapeutics in Q1 2026 and held it in 2 quarters.
- Stratos Wealth Partners's Gain Therapeutics position peaked at $406K in Q2 2026.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.
Based on Stratos Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.